Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka
Pharma
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
An injectable version of Leqembi faces an FDA delay. Novartis scored an expanded deal to manufacture Carvykti. An Ozempic biosim seeks a nod in China.
Angus Liu
Apr 5, 2024 8:25am
Big Pharma deal spree, China plans and more—Fierce Pharma Asia
Jan 5, 2024 8:44am
Novartis-Legend, Astellas, Ajinomoto—Fierce Pharma Asia
Nov 17, 2023 8:00am
FDA rules key Otsuka marketing claim overstates Rexulti efficacy
Nov 13, 2023 8:05am
AstraZeneca, Takeda, BioNTech—Fierce Pharma Asia
Nov 10, 2023 8:05am
Lundbeck, Otsuka dial down the drama for Rexulti agitation ad
Oct 13, 2023 9:45am